Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crenezumab - AC Immune/Genentech/Universidad-de-Antioquia

Drug Profile

Crenezumab - AC Immune/Genentech/Universidad-de-Antioquia

Alternative Names: Anti-Abeta antibody; MABT5102A; R 5490245; RG 7412; RO 5490245

Latest Information Update: 01 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AC Immune; Universidad de Antioquia
  • Developer AC Immune; Genentech; Universidad de Antioquia
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 29 Jan 2019 Genentech discontinues the phase III CREAD1 and CREAD2 trials in Alzheimers disease in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Costa Rica, Chile, China, Colombia, Croatia, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Hong Kong, Hungary, Italy, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Russia, Slovenia, Serbia, Slovakia, Spain, South Korea, Sweden, Switzerland, South Africa, Spain, Taiwan Turkey, Ukraine, the UK and the US due to unfavorable efficacy results
  • 29 Oct 2018 Pharmacodynamics data from an in vitro study in Alzheimer's disease released by AC Immune
  • 25 Jul 2018 Efficacy data from the ABBY and BLAZE phase II trials for Alzheimer's disease released by AC Immune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top